Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis and its treatment.

G Giovannoni1, D H Miller

  • 1Department of Clinical Neurosciences, Royal Free and University College Medical School, London. g.giovannoni@rfhsm.ac.uk

Journal of the Royal College of Physicians of London
|September 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurements of the exclusive decays of the upsilon(5S) to meson final states and improved B(s)* mass measurement.

Physical review letters·2006
Same author

Charmonium Decays of Y(4260), psi(4160), and psi(4040).

Physical review letters·2006
Same author

Observation of Psi(3770)-->gammachi(c1)-->gammagammaJ/Psi.

Physical review letters·2006
Same author

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

Neurology·2006
Same author

Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis.

Brain : a journal of neurology·2006
Same author

Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis.

Journal of neurology·2006
Same journal

A Change of Government and Its Effect on the NHS Hospital Outpatient Service.

Journal of the Royal College of Physicians of London·2019
Same journal

Erratum: Model for the Organisation of a Community-Based Rehabilitation Service.

Journal of the Royal College of Physicians of London·2019
Same journal

Telemedicine and beyond.

Journal of the Royal College of Physicians of London·2019
Same journal

Palliative Care in General Medicine.

Journal of the Royal College of Physicians of London·2019
Same journal

Medical Negligence.

Journal of the Royal College of Physicians of London·2019
Same journal

In Response.

Journal of the Royal College of Physicians of London·2019
See all related articles

Multiple sclerosis (MS) is a central nervous system autoimmune disease. While broad immunosuppression failed, immunomodulatory therapies like interferon-beta offer improved relapse and progression control for MS patients.

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a prevalent neurological disorder causing significant morbidity.
  • MS is characterized as an autoimmune demyelinating disease of the central nervous system (CNS).
  • Traditional generalized immunosuppression strategies have yielded disappointing results in MS treatment.

Purpose of the Study:

  • To review the immunopathogenesis of multiple sclerosis.
  • To discuss current therapeutic strategies for MS, including disease-modifying and symptomatic treatments.
  • To evaluate the effectiveness of recent immunomodulatory therapies.

Main Methods:

  • Literature review of MS immunopathogenesis.
  • Analysis of therapeutic strategies for MS.

Related Experiment Videos

  • Evaluation of immunomodulatory treatments such as interferon-beta and glatiramer acetate.

    • Main Results:

    • Immunomodulatory therapies, including interferon (IFN)-beta and glatiramer acetate, demonstrate greater efficacy than generalized immunosuppression.
    • IFN-beta and glatiramer acetate reduce the rate and severity of clinical relapses in MS patients.
    • IFN-beta has shown potential in delaying disease progression in multiple sclerosis.

    Conclusions:

    • Symptomatic therapies and rehabilitation remain crucial for managing MS symptoms.
    • Recent advances in immunomodulatory treatments offer improved outcomes for MS patients.
    • A comprehensive understanding of MS immunopathogenesis is vital for developing effective treatments.